TECON BIOLOGY CO.LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.25 CNY | +5.69% |
|
+7.41% | -17.33% |
| Apr. 29 | TECON BIOLOGY Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Tecon Biology's Pig Sales Revenue Climbs 12% in March | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,046 | 13,598 | 11,386 | 11,517 | 11,255 | 9,898 | 9,898 | - |
| Enterprise Value (EV) 1 | 4,046 | 13,598 | 15,808 | 14,888 | 15,009 | 15,185 | 14,262 | 14,406 |
| P/E ratio | 12.7 x | 21.3 x | 6.62 x | -17.3 x | 37.8 x | -8.68 x | 17.3 x | 7.57 x |
| Yield | 2.38% | - | 4.34% | - | 2.65% | - | 0.93% | 2.7% |
| Capitalization / Revenue | 0.77 x | 1.82 x | 0.95 x | 0.73 x | 0.67 x | 0.63 x | 0.46 x | 0.41 x |
| EV / Revenue | 0.77 x | 1.82 x | 1.32 x | 0.95 x | 0.9 x | 0.8 x | 0.67 x | 0.6 x |
| EV / EBITDA | 7.24 x | 14.7 x | 6.88 x | 103 x | 15 x | -24 x | 9.51 x | 5.37 x |
| EV / FCF | - | - | - | - | -14 x | 20.2 x | -91.4 x | 18.9 x |
| FCF Yield | - | - | - | - | -7.16% | 4.95% | -1.09% | 5.28% |
| Price to Book | 1.26 x | 2.97 x | 1.83 x | 2.03 x | 1.42 x | 1.38 x | 1.53 x | 1.15 x |
| Nbr of stocks (in thousands) | 963,402 | 1,063,994 | 1,075,135 | 1,076,337 | 1,354,339 | 1,365,252 | 1,365,252 | - |
| Reference price 2 | 4.200 | 12.78 | 10.59 | 10.70 | 8.310 | 7.250 | 7.250 | 7.250 |
| Announcement Date | 2/27/19 | 2/25/20 | 4/22/21 | 4/26/22 | 4/28/23 | 4/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,273 | 7,476 | 11,987 | 15,744 | 16,732 | 19,026 | 21,405 | 24,078 |
| EBITDA 1 | 558.7 | 924.8 | 2,297 | 144.3 | 1,002 | -632 | 1,499 | 2,684 |
| EBIT 1 | 333.2 | 590.7 | 1,808 | -599.9 | 276.6 | -1,446 | 991.3 | 1,558 |
| Operating Margin | 6.32% | 7.9% | 15.08% | -3.81% | 1.65% | -7.6% | 4.63% | 6.47% |
| Earnings before Tax (EBT) 1 | 334.4 | 589.9 | 1,808 | -646.5 | 235.8 | -1,493 | 908 | 1,467 |
| Net income 1 | 313.7 | 644.5 | 1,720 | -686 | 301.5 | -1,363 | 575 | 1,303 |
| Net margin | 5.95% | 8.62% | 14.35% | -4.36% | 1.8% | -7.17% | 2.69% | 5.41% |
| EPS 2 | 0.3300 | 0.6000 | 1.600 | -0.6200 | 0.2200 | -1.010 | 0.4200 | 0.9580 |
| Free Cash Flow 1 | - | - | - | - | -1,074 | 751.4 | -156 | 761 |
| FCF margin | - | - | - | - | -6.42% | 3.95% | -0.73% | 3.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 28.36% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 58.39% |
| Dividend per Share 2 | 0.1000 | - | 0.4600 | - | 0.2200 | - | 0.0673 | 0.1958 |
| Announcement Date | 2/27/19 | 2/25/20 | 4/22/21 | 4/26/22 | 4/28/23 | 4/28/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 4,422 | 3,371 | 3,754 | 3,212 | 4,364 | 4,508 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 1.925 x | 23.36 x | 3.746 x | -5.082 x | 2.911 x | 1.68 x |
| Free Cash Flow 1 | - | - | - | - | -1,074 | 751 | -156 | 761 |
| ROE (net income / shareholders' equity) | 10.2% | 16.8% | 31.9% | -11.7% | 4.07% | -19.2% | 7.15% | 14.1% |
| ROA (Net income/ Total Assets) | - | - | 12.8% | - | - | -8.2% | 3.49% | 7.1% |
| Assets 1 | - | - | 13,442 | - | - | 8,963 | 16,459 | 18,366 |
| Book Value Per Share 2 | 3.330 | 4.310 | 5.790 | 5.280 | 5.870 | 5.240 | 4.730 | 6.310 |
| Cash Flow per Share 2 | -1.220 | 0.2900 | -0.5600 | 1.130 | 0.2400 | 1.280 | 1.760 | 0.9700 |
| Capex 1 | 593 | 1,350 | 930 | 1,749 | 1,402 | 1,000 | 641 | 864 |
| Capex / Sales | 11.25% | 18.06% | 7.76% | 11.11% | 8.38% | 5.26% | 2.99% | 3.59% |
| Announcement Date | 2/27/19 | 2/25/20 | 4/22/21 | 4/26/22 | 4/28/23 | 4/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.25
CNY
Average target price
8.572
CNY
Spread / Average Target
+18.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.33% | 1.37B | |
| -5.94% | 266B | |
| -3.51% | 93.75B | |
| -1.70% | 44.14B | |
| +6.16% | 40.42B | |
| -1.60% | 39.92B | |
| +7.31% | 39.47B | |
| -18.07% | 29.26B | |
| -7.67% | 28.39B | |
| +12.84% | 25.04B |
- Stock Market
- Equities
- 002100 Stock
- Financials TECON BIOLOGY Co.LTD
